David S. Boss
Impact in
- Oncology top 1%
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
- Reproductive Medicine top 1%
- Ovarian cancer diagnosis and treatment
Papers in
- Oncology 6
- PARP inhibition in cancer therapy 3
-
- Microtubule and mitosis dynamics 2
- Co-authors
- Jan H.M. Schellens (13 shared papers)Stan B. Kaye (2 shared papers)Alan Ashworth (2 shared papers)James Carmichael (2 shared papers)Peter C.C. Fong (2 shared papers)Timothy Anthony Yap (2 shared papers)Andrew N.J. Tutt (2 shared papers)Marja Mergui‐Roelvink (2 shared papers)
- Journals
- Annals of Oncology (2 papers)The Oncologist (2 papers)Clinical Cancer Research (2 papers)Journal of Clinical Oncology (1 paper)The Lancet Regional Health - Europe (1 paper)
- Partner nations
- NetherlandsUnited KingdomUnited States
In The Last Decade
David S. Boss
17 papers receiving 4.6k citations
David S. Boss's Hit Papers
Peers
Comparison fields: 5 of 103
- Oncology 2.9k
- Reproductive Medicine 528
- Cancer Research 729
- Molecular Biology 2.3k
- Genetics 851
Countries citing papers authored by David S. Boss
This map shows the geographic impact of David S. Boss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David S. Boss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David S. Boss more than expected).
Fields of papers citing papers by David S. Boss
This network shows the impact of papers produced by David S. Boss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David S. Boss. The network helps show where David S. Boss may publish in the future.
Co-authors
The 25 scholars most cited alongside David S. Boss, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers Hit paper breakdown → | 2009 | 3057 |
| 2 | Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval Hit paper breakdown → | 2010 | 849 |
| 3 | 2011 | 165 | |
| 4 | 2012 | 165 | |
| 5 | 2010 | 97 | |
| 6 | 2009 | 88 | |
| 7 | 2009 | 64 | |
| 8 | 2009 | 52 | |
| 9 | 2008 | 47 | |
| 10 | 2005 | 38 | |
| 11 | 2010 | 14 | |
| 12 | 2011 | 13 | |
| 13 | 2023 | 12 | |
| 14 | 2015 | 9 | |
| 15 | 2017 | 7 | |
| 16 | 2013 | 5 | |
| 17 | 2009 | 1 | |
| 18 | 2026 | 0 |
About David S. Boss
David S. Boss is a scholar working on Oncology, Cell Biology, Infectious Diseases, Applied Microbiology and Biotechnology and Radiology, Nuclear Medicine and Imaging, having authored 18 papers that have together received 4.7k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (3 papers), SARS-CoV-2 and COVID-19 Research (2 papers), Microtubule and mitosis dynamics (2 papers), Cancer therapeutics and mechanisms (2 papers), Viral gastroenteritis research and epidemiology (1 paper), Animal Virus Infections Studies (1 paper), Glycosylation and Glycoproteins Research (1 paper) and Medical Imaging Techniques and Applications (1 paper). The work is most often cited by research in Oncology (2.9k citations), Reproductive Medicine (528 citations), Cancer Research (729 citations), Molecular Biology (2.3k citations) and Genetics (851 citations). David S. Boss has collaborated with scholars based in Netherlands, United Kingdom and United States. Frequent co-authors include Jan H.M. Schellens, Stan B. Kaye, Alan Ashworth, James Carmichael, Peter C.C. Fong, Timothy Anthony Yap, Andrew N.J. Tutt, Marja Mergui‐Roelvink, Johann Sebastian De Bono and Helen Swaisland. Their work appears in journals such as Annals of Oncology, The Oncologist, Clinical Cancer Research, Journal of Clinical Oncology and The Lancet Regional Health - Europe.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.